Merck to Join Rivals on Immune Cancer Drug Development

▲Click for full story

The collaboration boosted Merck’s shares after the company reported fourth-quarter earnings that fell short of estimates. Earnings excluding certain items were 88 cents a share, 1 cent below the average of 15 analysts’ estimates compiled by Bloomberg. The Whitehouse, New Jersey-based company also forecast 2014 profit of $3.35 a share to $3.53 a share, compared with $3.48 projected by analysts. “


By Drew Armstrong,  Photographer: Emile Wamsteker/Bloomberg